Efficacy of Repaglinide in Subjects With Type 2 Diabetes
NCT ID: NCT01698931
Last Updated: 2017-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
9 participants
INTERVENTIONAL
2002-04-26
2003-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00118963
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
NCT01465152
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118950
Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes
NCT01720290
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
NCT00568984
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment period 1
repaglinide
1 mg before each main meal on three separate dosing visits separated by a wash-out period
glyburide
5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
placebo
Before each main meal on three separate dosing visits separated by a wash-out period
Treatment period 2
repaglinide
1 mg before each main meal on three separate dosing visits separated by a wash-out period
glyburide
5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
placebo
Before each main meal on three separate dosing visits separated by a wash-out period
Treatment period 3
repaglinide
1 mg before each main meal on three separate dosing visits separated by a wash-out period
glyburide
5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
placebo
Before each main meal on three separate dosing visits separated by a wash-out period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repaglinide
1 mg before each main meal on three separate dosing visits separated by a wash-out period
glyburide
5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
placebo
Before each main meal on three separate dosing visits separated by a wash-out period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c (glycosylated haemoglobin A1c) above 7 %
* BMI (body mass index) below 32 kg/m\^2
* FBG (fasting blood glucose) after wash out period 130-220 mg/dl
* Currently treated with diet or OHA (oral hypoglycaemic agent)
Exclusion Criteria
* Known or suspected history of drug or alcohol dependence
* Any other significant concomitant disease such as cerebrovascular or symptomatic peripheral vascular disease, malignant, disease or severe treated or untreated hypertension
* Hepatic disease
* Cardiac problems
* Active proliferative retinopathy
* Known or suspected allergy to trial product or related products
* Women in fertile age and women having the intention of becoming pregnant
* Body Mass Index (BMI) above 32 kg/m\^2
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Padua, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ciccarone A, Mari A, Pulizzi N, Bianchi C, Palumbo F, Benzi L, Del Prato S. Assessment of insulin secretion in response to a mixed meal in type 2 diabetes. Effects of short-term repaglinide and glibenclamide administration. Diabetologia 2005; 48 (Suppl. 1): A284 (Abstract No. PS65-781)
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGEE-1259
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.